Sex Differences in Childhood Atopic Disease and the Role of Sex-Steroid Metabolites

Studies have described sex differences in childhood asthma, allergy, and atopic dermatitis, but the development and clinical phenotype of these differences remain poorly understood.

To characterize sex differences in atopic disease throughout childhood and study the potential role of sex-steroid metabolites.

We examined sex differences in asthma, allergy, and atopic dermatitis using longitudinal generalized estimating equation models in the Copenhagen Prospective Studies on Asthma in Childhood (COPSAC)₂₀₀₀ (n = 411) and COPSAC₂₀₁₀ (n = 700) birth cohorts. We further examined possible mechanisms through early life sex-steroid metabolites.

In combined analyses of COPSAC₂₀₀₀ and COPSAC₂₀₁₀ until age 6 years, males had a higher prevalence of asthma compared with females (25% vs 20%, odds ratio = 1.48; 95% CI, 1.09-2.02) and experienced more asthma exacerbations (incidence rate ratio = 1.87; 95% CI, 1.37-2.55). Males had a higher prevalence of allergic sensitization (37% vs 31%; odds ratio = 1.54; 95% CI, 1.20-1.98) and higher blood eosinophil count (geometric mean ratio = 1.16; 95% CI, 1.07-1.27), which may indicate type 2 inflammation. These sex differences persisted until age 18 years in COPSAC₂₀₀₀, except for asthma prevalence, whereas males had a higher prevalence of allergic rhinitis and a higher FeNO. During preschool age, five of the measured sex-steroid metabolites significantly mediated parts of the sex differences in allergic sensitization (range of proportion mediated, 0.16-0.18) and/or blood eosinophils (range of proportion mediated, 0.22-0.25).

Males had a higher prevalence of asthma, more frequent asthma exacerbations, higher prevalence of allergic sensitization, and higher blood eosinophil count compared with females during early childhood across two birth cohorts. These sex differences, which may indicate type 2 inflammation, persisted into adolescence and were partly explained by sex-steroid metabolites.